DK0818204T3 - Stabiliseret albuminfri rekombinant faktor VIII præparat med et lavt sukkerindhold - Google Patents

Stabiliseret albuminfri rekombinant faktor VIII præparat med et lavt sukkerindhold

Info

Publication number
DK0818204T3
DK0818204T3 DK97110631T DK97110631T DK0818204T3 DK 0818204 T3 DK0818204 T3 DK 0818204T3 DK 97110631 T DK97110631 T DK 97110631T DK 97110631 T DK97110631 T DK 97110631T DK 0818204 T3 DK0818204 T3 DK 0818204T3
Authority
DK
Denmark
Prior art keywords
factor viii
sugar content
low sugar
recombinant factor
viii preparation
Prior art date
Application number
DK97110631T
Other languages
Danish (da)
English (en)
Inventor
Rajiv Nayar
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0818204T3 publication Critical patent/DK0818204T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK97110631T 1996-07-12 1997-06-30 Stabiliseret albuminfri rekombinant faktor VIII præparat med et lavt sukkerindhold DK0818204T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/678,492 US5763401A (en) 1996-07-12 1996-07-12 Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Publications (1)

Publication Number Publication Date
DK0818204T3 true DK0818204T3 (da) 2000-07-17

Family

ID=24723010

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97110631T DK0818204T3 (da) 1996-07-12 1997-06-30 Stabiliseret albuminfri rekombinant faktor VIII præparat med et lavt sukkerindhold

Country Status (30)

Country Link
US (2) US5763401A (xx)
EP (1) EP0818204B1 (xx)
JP (1) JP4077055B2 (xx)
KR (1) KR100491281B1 (xx)
CN (1) CN1130224C (xx)
AR (1) AR007845A1 (xx)
AT (1) ATE191146T1 (xx)
AU (1) AU718901B2 (xx)
BR (1) BR9704407B1 (xx)
CA (1) CA2210038C (xx)
CO (1) CO4700302A1 (xx)
CZ (1) CZ292183B6 (xx)
DE (1) DE69701548T2 (xx)
DK (1) DK0818204T3 (xx)
ES (1) ES2144293T3 (xx)
GR (1) GR3033669T3 (xx)
HU (1) HU221415B1 (xx)
ID (1) ID19074A (xx)
IL (1) IL121273A (xx)
MY (1) MY125544A (xx)
NZ (1) NZ328297A (xx)
PL (1) PL186950B1 (xx)
PT (1) PT818204E (xx)
RU (1) RU2201252C2 (xx)
SG (1) SG50864A1 (xx)
SK (1) SK282207B6 (xx)
TR (1) TR199700628A2 (xx)
TW (1) TW381027B (xx)
UA (1) UA43882C2 (xx)
ZA (1) ZA976167B (xx)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
MXPA01008515A (es) 1999-02-22 2003-06-06 Baxter Int Formulaciones novedosas de factor viii libres de albumina.
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
PL356817A1 (en) * 1999-12-30 2004-07-12 Intermune Inc. Gamma-ifn liquid-droplet aerosol and method
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
WO2003055512A1 (en) 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
RU2366451C2 (ru) * 2002-06-21 2009-09-10 Ново Нордиск Хелт Кэр Аг Стабилизированные твердые композиции полипептидов фактора vii
WO2004039392A2 (en) * 2002-10-29 2004-05-13 Alza Corporation Stabilized, solid-state polypeptide particles
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
CA2545458A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
SI2298287T1 (en) * 2003-12-19 2018-08-31 Novo Nordisk Health Care Ag Stabilized compositions of factor VII polypeptides
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
JP2007526329A (ja) * 2004-03-04 2007-09-13 ワイス 賦形剤の結晶化を改善するための凍結乾燥法
PL1745078T3 (pl) 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Sposób oczyszczania koniugatów albumin
EP1750733B1 (en) 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
PT1778723E (pt) * 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
WO2006096497A2 (en) * 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
SI1861116T1 (sl) 2005-03-25 2015-12-31 Regeneron Pharmaceuticals, Inc. Formulacije antagonistov VEGF
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
US20070237758A1 (en) * 2005-11-22 2007-10-11 Anthony Barry Immunoglobulin fusion protein formulations
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
LT2944306T (lt) 2006-06-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu
PL2101821T3 (pl) * 2006-12-15 2015-01-30 Baxalta Inc Koniugat czynnik viia-(poli)kwas sjalowy o przedłużonym okresie półtrwania in vivo
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
EP2150264A4 (en) * 2007-04-26 2014-09-24 Bayer Healthcare Llc STABILIZATION OF LIQUID SOLUTIONS OF A RECOMBINANT PROTEIN FOR FROZEN STORAGE
AU2008260483A1 (en) * 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
BRPI0917656A2 (pt) 2008-08-21 2017-07-11 Octapharma Ag Fatores viii e ix humanos produzidos de forma recombinante
BRPI0918589B1 (pt) * 2008-09-03 2021-07-13 Octapharma Ag Composições de proteção para fator viii recombinantemente produzido
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
RU2589254C2 (ru) 2009-06-09 2016-07-10 ПРОЛОНГ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Композиции гемоглобина
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
EA035447B1 (ru) 2010-11-05 2020-06-17 Баксалта Инкорпорейтид Выделенный рекомбинантный вариант фактора viii (fviii) с частично удаленным в-доменом
AU2011352161B2 (en) * 2010-12-28 2016-10-20 E. I. Du Pont De Nemours And Company A fabric prepared from fluorinated polyester blend yarns
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN102430116A (zh) * 2011-08-19 2012-05-02 上海新兴医药股份有限公司 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂
JP6523244B2 (ja) 2013-03-15 2019-05-29 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 変異体第ｖｉｉｉ因子ポリペプチドならびにそれらの製造方法および使用方法
SG10201805207QA (en) 2013-03-15 2018-07-30 Bioverativ Therapeutics Inc Factor viii polypeptide formulations
EP2970430A4 (en) * 2013-03-15 2017-01-11 Bayer HealthCare LLC Recombinant factor viii formulations
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
CA2944183A1 (en) 2014-04-01 2015-10-08 Advantech Bioscience Farmaceutica Ltda. Stabilization of factor viii without calcium as an excipient
CN106413741A (zh) * 2014-04-01 2017-02-15 爱德技术生物科学有限公司 含低糖‑甘氨酸的稳定因子viii制剂
MX2017000840A (es) 2014-07-18 2017-05-04 Sanofi Sa Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
NZ729629A (en) * 2014-08-04 2021-12-24 Csl Ltd Factor viii formulation
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
WO2017076967A1 (en) * 2015-11-05 2017-05-11 Novo Nordisk A/S Fviii formulation
CN106139127B (zh) * 2016-08-05 2020-04-07 无锡药明生物技术股份有限公司 重组凝血因子ⅷ冻干制剂
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4847362A (en) * 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5399670A (en) * 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
EP0627924B1 (en) * 1992-10-02 2000-12-27 Genetics Institute, Inc. Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Also Published As

Publication number Publication date
GR3033669T3 (en) 2000-10-31
ES2144293T3 (es) 2000-06-01
PL321058A1 (en) 1998-01-19
BR9704407A (pt) 2000-06-06
HUP9701191A3 (en) 2000-08-28
HUP9701191A2 (hu) 1999-06-28
RU2201252C2 (ru) 2003-03-27
JPH1067679A (ja) 1998-03-10
NZ328297A (en) 1999-09-29
SK92197A3 (en) 1998-02-04
ID19074A (id) 1998-06-11
IL121273A0 (en) 1998-01-04
AR007845A1 (es) 1999-11-24
KR100491281B1 (ko) 2005-08-05
CO4700302A1 (es) 1998-12-29
AU718901B2 (en) 2000-04-20
US5763401A (en) 1998-06-09
MY125544A (en) 2006-08-30
TW381027B (en) 2000-02-01
EP0818204A3 (en) 1998-02-04
MX9705209A (es) 1998-05-31
HU9701191D0 (en) 1997-08-28
DE69701548D1 (de) 2000-05-04
PT818204E (pt) 2000-08-31
CZ219497A3 (cs) 1998-01-14
CN1130224C (zh) 2003-12-10
SK282207B6 (sk) 2001-12-03
HU221415B1 (en) 2002-09-28
ZA976167B (en) 1998-02-02
JP4077055B2 (ja) 2008-04-16
PL186950B1 (pl) 2004-04-30
UA43882C2 (uk) 2002-01-15
CN1181974A (zh) 1998-05-20
US5874408A (en) 1999-02-23
IL121273A (en) 2000-09-28
SG50864A1 (en) 1998-07-20
EP0818204A2 (en) 1998-01-14
EP0818204B1 (en) 2000-03-29
AU2860497A (en) 1998-01-22
KR980008241A (ko) 1998-04-30
BR9704407B1 (pt) 2010-03-09
CA2210038C (en) 2007-03-13
TR199700628A2 (xx) 1998-01-21
CA2210038A1 (en) 1998-01-12
ATE191146T1 (de) 2000-04-15
CZ292183B6 (cs) 2003-08-13
DE69701548T2 (de) 2000-07-27

Similar Documents

Publication Publication Date Title
DK0818204T3 (da) Stabiliseret albuminfri rekombinant faktor VIII præparat med et lavt sukkerindhold
PL317761A1 (en) In yeast exprimed proteins elongated at the end n
GB9408500D0 (en) Improvements in or relating to injection devices
HRP970298B1 (en) Interferon conjugates
EP0557455A4 (en) Recombinant feline coronavirus s proteins
DE69207357D1 (de) Stabilisierte Polyester-Polycarbonat-Mischungen
AU2923792A (en) Asymmetric whirl combustion
NO974924D0 (no) Modifiserte polypeptider med öket immunogenisitet
IL113725A0 (en) Preparing recombinant aprotini and its variants
EP0695939A3 (de) Regensensor
EP0324256A3 (en) Improvements in ventilators
AU5597998A (en) Recombinant plague vaccine
GB9105509D0 (en) Improvements in or relating to support arrangements
AU174P (en) OXLEY Glycine max
GB9420877D0 (en) Improvements in refractories
TW325675U (en) Floss stick with detachable structure
HU513U (en) Toy with spinning top
AU23P (en) A5939 Glycine max
AU26P (en) MANARK Glycine max
AU24P (en) A5474 Glycine max
ZA945843B (en) Recombinant adenovirus vaccines
HU9600224D0 (en) Reis with chocholate
SE9400743D0 (sv) Silos med jämn lutning
GB9114774D0 (en) Improvements in or relating to proteins
GB9112655D0 (en) The runner rat